DEXCOM G6 CGM
DeviceAll women in the study will be given Dexcom G6 CGM and a study glucometer.
NCT Number: NCT03761615
The overall goal of this study is to enroll pregnant women with type 1 diabetes and follow their glycemic outcomes prospectively throughout pregnancy and into the post-partum period. The investigators anticipate that when compared to subjects using an Artificial pancreas system (AP) as part of a future protocol, this comparator group of subjects undergoing usual care will exhibit less time in target continuous glucose monitoring (CGM) glucose range defined as 63-140 mg/dL and an increased duration of hypoglycemia with CGM glucose <63 mg/dL.
Looking for future studies?
Notify Me18 year–40 year
Female
Observational
Sansum Diabetes Research Institute, Santa Barbara, California, United States
This is an observational study. Data collected will include records of continuous glucose monitoring (CGM) based glucose, insulin delivery, self-monitoring of blood glucose (SMBG), and maternal and fetal outcomes from pregnant women with type 1 diabetes. These data will be used to: (1) develop and refine algorithms for an AP system tailored to the needs of pregnant women with type 1 diabetes, (2) to serve as a comparator group for concurrent AP protocols, (3) describe Dexcom G6 CGM data throughout the pregnancy, and (4) describe insulin changes which occur in pregnancy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All women in the study will be given Dexcom G6 CGM and a study glucometer.
Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum
Time in range defined as 63-140 mg/dL as determined by CGM analysis
Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum
Time spent below target cgm glucose range defined as glucose <63 mg/dL
Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum
Time spent above target cgm glucose range defined as >140 mg/dL
Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum
Episodes of clinically significant hyperglycemia with CGM glucose >180 mg/dL
Time frame: 2 weeks
Total daily insulin requirements (units/kg/day) over last 2 weeks of third trimester
Time frame: 2 weeks
Basal daily insulin requirements (units/kg/day) over last 2 weeks of third trimester
Time frame: 2 weeks
Carbohydrate consumption (g/(kg*day)) over last 2 weeks of third trimester
Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum
Episodes of ketoacidosis requiring emergency room or hospital admission
Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum
Maternal complications including preeclampsia, pregnancy induced hypertension and polyhydramnios
Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum
Gestational weight gain each week
Time frame: Immediately at birth
Gestational age at delivery (Weeks)
Time frame: Immediately at birth
Birth weight of baby (kg)
Time frame: Immediately at birth
Number of Large for Gestational Age based on WHO criteria at time of delivery
Time frame: Immediately at birth
Number of infants born late preterm birth (at 34-37 weeks)
Time frame: Prior to 17 weeks gestation (enrollment) through up to 6 weeks postpartum
Number of infants requiring neonatal NICU stay
Time frame: Immediately at birth
Number of participants that underwent primary cesarean section for delivery
Sansum Diabetes Research Institute
Other
Observational Study of Patient Important Outcomes in Pregnant Patients With Type 1 Diabetes Mellitus on Insulin Pump
Acronym: LOIS-P
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00639964
Autoimmune Diseases, Diabetes Mellitus
Lille, France
View Trial DetailsNCT03774186
Autoimmune Diseases, Diabetes Mellitus
Aurora, Colorado, United States
View Trial DetailsNCT07696039
Autoimmune Diseases, Diabetes Mellitus
Bergamo, Italy
View Trial DetailsNCT03263494
Autoimmune Diseases, Diabetes Mellitus
Los Angeles, California, United States
View Trial Details